Ibrutinib, the first BKTi product on the market, enhances efficacy in combination with anti-CD19 CAR-T cells.152,153 The concomitant administration of CAR-T-cell therapy and ibrutinib led to a higher ORR (83%) than CAR-T-cell therapy alone (56%).154 In mouse experiments, ibrutinib had a synergistic effect when combined with CD19 CAR-T cells; the CAR-T cells in the mice were significantly expanded, and the proportion of expansion was higher than with CAR-T-cell treatment alone, significantly reducing the tumor load.153. Here, CD19 is linked to neoplasm.